Matthew D. Witkin

1.6k total citations
8 papers, 365 citations indexed

About

Matthew D. Witkin is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Matthew D. Witkin has authored 8 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Hematology and 1 paper in Genetics. Recurrent topics in Matthew D. Witkin's work include Epigenetics and DNA Methylation (4 papers), Acute Myeloid Leukemia Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Matthew D. Witkin is often cited by papers focused on Epigenetics and DNA Methylation (4 papers), Acute Myeloid Leukemia Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Matthew D. Witkin collaborates with scholars based in United States and Germany. Matthew D. Witkin's co-authors include Scott A. Armstrong, Andrei V. Krivtsov, Richard P. Koche, Ross L. Levine, Sheng F. Cai, Ulrich Steidl, Monica Cusan, Tina Davis, Jay L. Hess and Min Ye and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

Matthew D. Witkin

8 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew D. Witkin United States 6 286 109 81 47 43 8 365
Ashley N. Kamimae-Lanning United States 7 317 1.1× 49 0.4× 53 0.7× 59 1.3× 88 2.0× 8 415
Anja Hohmann United States 5 429 1.5× 94 0.9× 71 0.9× 42 0.9× 30 0.7× 9 474
Ling Sun China 11 201 0.7× 81 0.7× 68 0.8× 61 1.3× 118 2.7× 19 338
Miriam Kull Germany 8 279 1.0× 130 1.2× 61 0.8× 19 0.4× 17 0.4× 16 335
Sofia Vidal‐Cardenas United States 5 207 0.7× 48 0.4× 50 0.6× 29 0.6× 22 0.5× 7 316
Laura Godfrey United States 8 319 1.1× 75 0.7× 114 1.4× 19 0.4× 40 0.9× 11 418
Xiongpeng Zhu China 9 207 0.7× 128 1.2× 73 0.9× 48 1.0× 38 0.9× 24 345
Mohammad Alzrigat Sweden 9 260 0.9× 122 1.1× 42 0.5× 42 0.9× 60 1.4× 15 317
Amanda L. Robichaud United States 7 280 1.0× 36 0.3× 105 1.3× 28 0.6× 47 1.1× 9 370

Countries citing papers authored by Matthew D. Witkin

Since Specialization
Citations

This map shows the geographic impact of Matthew D. Witkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Witkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Witkin more than expected).

Fields of papers citing papers by Matthew D. Witkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Witkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Witkin. The network helps show where Matthew D. Witkin may publish in the future.

Co-authorship network of co-authors of Matthew D. Witkin

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Witkin. A scholar is included among the top collaborators of Matthew D. Witkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Witkin. Matthew D. Witkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Smith, Julianne, Matthew D. Witkin, Alvin Jogasuria, et al.. (2020). Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis. Scientific Reports. 10(1). 11657–11657. 23 indexed citations
2.
Huang, Yun-Han, Jing Hu, Fei Chen, et al.. (2019). ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. Cancer Discovery. 10(1). 142–157. 49 indexed citations
3.
Cusan, Monica, Sheng F. Cai, Helai P. Mohammad, et al.. (2018). LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 131(15). 1730–1742. 81 indexed citations
4.
Sun, Yuqing, Bo Zhou, Fengbiao Mao, et al.. (2018). HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell. 34(4). 643–658.e5. 86 indexed citations
5.
Park, Sun‐Mi, Hyunwoo Cho, Angela M. Thornton, et al.. (2018). IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell stem cell. 24(1). 153–165.e7. 65 indexed citations
6.
Krivtsov, Andrei V., Benjamin K. Eschle, Matthew D. Witkin, et al.. (2018). Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Research. 78(13_Supplement). 4958–4958. 1 indexed citations
7.
Chu, S. Haihua, Jonathan Chabon, Richard P. Koche, et al.. (2016). Loss of Lysine Histone Methyltransferase Setd2 Disrupts Normal Hematopoiesis, Lineage Commitment and Reveals a Novel Role for H3K36me3 in Immunoglobulin VDJ Recombination. Blood. 128(22). 423–423. 1 indexed citations
8.
Stubbs, Matthew C., Won-Il Kim, Tina Davis, et al.. (2015). Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research. 21(10). 2348–2358. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026